The "Contract Manufacturing in Pharmaceutical Industry, 2015 - 2025" report provides an extensive study of the rapidly growing pharmaceutical contract manufacturing market. With pharmaceutical and ...
"GAAP net income attributable to Biogen Inc." CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2015 results, including full year revenues of ...
PARIS--(BUSINESS WIRE)--Regulatory News: OSE Pharma SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE), an immuno-oncology company developing a T-specific immunotherapy, currently in a registration Phase ...
AstraZeneca ADR announced Thursday that it will buy at 55% stake in biotech company Acerta Pharma. AstraZeneca will pay an initial $2.5 billion for the stake and a further $1.5 billion upon the ...
Newly released statistics (2015-06-30 PTAB Statistics) from the USPTO reveal that the number of bio/pharma IPR challenges almost doubled in 2015, even though fiscal year 2015 still has three months to ...
As the drumbeat for drug pricing reform has grown, two things are becoming clear: This issue is not going away, and Pharma’s time-worn rebuttals are increasingly unlikely to save the industry from ...
Many pharma critics argue that drug companies skimp on research while earning outsize revenues–but a new analysis my colleague and I just published tells a more nuanced story. Instead, it's more ...
AstraZeneca plcAZN confirmed, in response to a speculation, that it is exploring strategic options with Acerta Pharma BV. On Dec 11, 2015, the Wall Street Journal had reported that AstraZeneca is in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results